DMD #1198
Introduction 1-(2-Pyrimidinyl)-piperazine (1-PP 1 ) is a major active metabolite resulting from the Ndealkylation of several antidepressant/anxiolytic 5-HT 1A agonists including tandospirone, gepirone, ipsapirone, and buspirone Caccia et al., 1986; Caccia et al., 1985; Koenig et al., 1988) . 1-PP is up to 20% as active as buspirone in in vitro pharmacological models for buspirone and in in vivo anxiolytic and α 2 -adrenoceptor antagonist activity (Garattini et al., 1982; Caccia et al., 1986; Berlin et al., 1995) . In addition, 1-PP has an affinity for α 2 -adrenergic receptor with K d =40 nM and for the 5-HT 1A with K d =1035 nM (Gobert et al., 1995) . 1-PP was a partial agonist for 5-HT 1A and an antagonist for the α 2 -adrenergic receptor and induced hyperthermic response in rats (Komissarev et al., 1990) . The concentration of 1-PP in rat brain after oral administration of buspirone was 15-30 times higher than the concentration of buspirone (Gammans et al., 1983) . The human plasma levels of 1-PP (ng/mL) were approximately 4-fold higher than buspirone following a 20 mg effective oral dose of buspirone. Elimination of 1-PP appeared to be much slower than that of buspirone in humans (Gammans et al., 1986; Goldberg and Finnerty, 1979) .
Metabolism of buspirone in humans has been reported (Jajoo et al., 1989) . Following administration of a 20 mg oral dose in humans, 60% of the dose was excreted in urine.
HO-1-PP represented a major urinary metabolite (7-19% of the dose). Incubation with microsomal preparations. The incubations were done in triplicates in a total volume of 0.25 mL. HLMs with different CYP2D6 activities (low, midium, and high) and the human cDNA-expressed CYP isozymes (CYP2D6, 3A4, 1A2, 2A6, 2C9, 2C19, 2E1, and 2B6) were carefully thawed, mixed well, and placed on ice prior to the experiment. 1-PP at a concentration of 100 µM was incubated with HLM preparations at the final protein concentration of 0.5 mg/mL (HLM), 200 pmole CYPs (3A4, 1A2, 2A6, DMD #1198   7 2C9, 2C19, 2E1, and 2B6), or various amounts of CYP2D6 in 0.1 M phosphate buffer (pH 7.4). The concentrations of 1-PP were 5, 7.5, 15, 30, 50, 100, 150, 225, 300, 400, 500, 750 , and 1000 µM to determine enzyme kinetic parameters. Incubations were also performed in the presence of the inhibitor ketoconazole (1 and 5 µM) or quinidine (1 and 5 µM) at a 1-PP concentration of 100 µM in the inhibition studies. To determine the effect of heat-inactivated HLM proteins on the cDNA-expressed CYP2D6 activities, the pooled HLM in a glass tube was incubated for 5 min in boiled water before added to the incubations with the expressed CYP2D6. NADPH was added to the incubation mixture at a final concentration of 1.2 mM. The incubation mixture was incubated in a water bath at 37 o C for 15 min. At the end of the incubation period, acetonitrile (0.25 mL) was added to each sample. The mixtures were vortexed and allowed to sit in an ice-water bath for 2 hours. The supernatant (0.175 mL) was removed and the internal standard (0.025 mL) was added to the solution to a final concentration of 12.5 ng/mL. Dilution quality control samples were prepared by diluting the supernatant (0.020 mL) with 5 mM ammonium formate/acetonitrile (50:50) to give 1:10 dilution and the internal standard (0.025 mL) was added to a final concentration of 12.5 ng/mL. The samples were vortexed, and centrifuged for 10 min at 3000 rpm. A 10 µL portion of the sample was injected and analyzed by LC/MS/MS. Under these conditions, the HO-1-PP formation rates were linear with time and protein concentrations used.
Preparation of Standards.
A stock solution of 1-PP (15 mM) was prepared in water.
Stock solutions (1 mg/mL) of HO-1-PP and the internal standard were prepared in methanol. A 100 ng/mL working internal standard solution was prepared in acetonitrile/5 mM ammonium formate, pH 3.5 (50:50, v/v) from the stock solution.
This article has not been copyedited and formatted. The final version may differ from this version. Working solutions of HO-1-PP (10, 1, 0.1 and 0.01 µg/mL) from the stock solution were prepared in acetonitrile/5 mM ammonium formate, pH 3.5 (50:50, v/v) . Calibration standards were prepared by spiking the working solutions to a mixture containing 0.5 mg/mL microsomes, 100 mM phosphate buffer, pH 7.4 and 50% acetonitrile in 1 mL final volume to give 1000, 500, 200, 100, 50, 25, 10, 5, 1, and 0.5 ng/mL of HO-1-PP concentrations. Quality control samples were prepared from 10, 1 and 0.01 µg/mL working solutions to give 800, 500, 80, and 1 ng/mL HO-1-PP concentrations. All quality control and calibration standard samples were used on the day of preparation. A dilution quality control sample (1000 ng/mL) was prepared in HLM and diluted 40 times to give a concentration of 25 ng/mL. The samples were vortexed, and centrifuged for 10 min at 3000 rpm. A 10 µL portion of the sample was injected and analyzed by LC/MS/MS. This article has not been copyedited and formatted. The final version may differ from this version. 
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Results
For quantitation of HO-1-PP in microsomal incubations, calibration standard curves for HO-1-PP (ranging from 0.5 to 1000 ng/mL) were linear with R 2 values of ≥0.996. The mean observed concentrations of the analytical quality control samples showed less than 0.04% deviation from the nominal concentration. The overall coefficients of variation between and within-day variability of the analytical quality controls were <9%. The liver is generally the major organ involved in CYP-mediated metabolism, but these enzymes are also present in extrahepatic tissues such as brains (Miksys et al., 2002) and there is increasing evidence that they may contribute to the local in situ metabolism of drugs (Krishna and Klotz, 1994) . CYP2D6 has an high inter-individual variability and much of this variability is attributed to the genetic polymorphism of CYP2D6.
Aproximately 10% of Caucasians show a poor metabolizer phenotype of CYP2D6 due to inactive mutant alleles (Myer et al., 1990) . CYP2D6 metabolizes a number of central 
